Categories
Credit Cards

Merrill Lynch Stick to Their Buy Rating for CVS Health Corp

Merrill Lynch analyst Michael Cherny maintained a Buy rating on CVS Health Corp (NYSE:CVS) on Tuesday, setting a price target of eighty three dolars, which is approximately 9.11 % above the existing share price of $76.07.

Cherny expects CVS Health Corp to post earnings per share (EPS) of $0.93 for the earliest quarter of 2021.

The present consensus among eleven TipRanks analysts is for a modest Buy rating of shares in CVS Health, with an average price target of eighty four dolars.

The analysts priced targets range from a high of $101 to a low of $61.

In the latest earnings report of its, released on 09/30/2020, the company found a quarterly revenue of $67.06 billion and a net gain of $3.25 billion. The company’s market cap is actually $99.57 billion.

According to TipRanks.com, Merrill Lynch analyst Michael Cherny is now ranked with 4 stars on a 0 5 stars ranking scale, with an average return of 11.5 % and a 60.53 % success rate.

CVS Health Corp. engages in the provision of health care services. It runs through the following segments: Pharmacy Services, retail or Long Term Care, Health Care Benefits, and Corporate. The Pharmacy Services segment provides pharmacy benefit management solutions. The retail or Long Term Care segment includes offering of prescription medications as well as assortment of general merchandise.

The Health Care Benefits segment offers traditional, voluntary and consumer-directed health insurance products and similar services, which includes medical, pharmacy, dental, behavioural health, healthcare relief capabilities. The Corporate segment involves in providing management and administrative services. The company was founded by Stanley P. Goldstein as well as Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.

Leave a Reply

Your email address will not be published. Required fields are marked *